Navigation Links
Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors
Date:5/16/2013

NEW YORK, May 16, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

 

Competitor Analysis: Therapeutic Proteins – Biosimilars, Biobetters & Biosuperiors

http://www.reportlinker.com/p01171947/Competitor-Analysis-Therapeutic-Proteins-–-Biosimilars-Biobetters--Biosuperiors.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biopharmaceutical

 

Product Description

 

The new Competitive Intelligence Report Therapeutic Proteins – Biosimilars, Biobetters & Biosuperiors of May 2013 provides a competitor analysis of the product portfolios and development pipelines of ten major classes of therapeutic proteins and their biosimilar and biobetter/biosuperior versions in regulated and less regulated markets:

 

• Erythropoiesis Stimulating Agents (ESA)

• G-CSF & GM-CSF

• Thrombopoietin & Thrombopoiesis Stimulating Agents

• Interferon

• Insulin

• Coagulation Factors

• Human Growth Hormone (hGH)

• FSH etc

• Thrombolytics & Fibrinolytics

• Enzyme Replacement Therapies

 

Territories covered are the major pharmaceutical markets North America, Europe and Japan, as well as South Korea, India, China and other countries in Latin America, Africa and Australasia.

 

With more than US$ 50 bln in sales, therapeutic proteins represent a major category of pharmaceutical products with established therapeutic value and high economic attractiveness. As more and more of the branded products are running out of patent protection and regulatory agencies are providing better guidance, development of biosimilar versions as well as of improved next generation versions are a highly attractive goal for pharmaceutical and biotechnology as well as technology focused companies.

 

This report includes a compilation of current active projects in research and development of biosimilar and novel biobetter/biosuperior therapeutic proteins as well as non-protein based competitor products and an overview of approved products in regulated and less regulated markets.

 

Competitor projects are listed in a tabular format providing Information on:

 

• Drug Codes,

• Target / Mechanism of Action,

• Class of Compound,

• Company,

• Product Category,

• Indication,

• R&D Stage and

• additional comments with a hyperlink leading to the source of information.

 

About Competitor Analysis Series:

 

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

 

 

 

Table of Contents

 

1) Erythropoiesis Stimulating Agents (ESA)

 

• First generation epoetins in regulated markets

• Second generation epoetins in regulated markets

• Epoetin biosimilars in regulated markets

• Darbepoetin biosimilars in regulated markets

• Next generation biologic Eythropoiesis Stimulating Agents (ESA) in regulated markets

• Next generation small molecule Erythropoiesis Stimulating Agents

• First generation EPO in less regulated markets (Central & South America;

Africa;

Asia;

Rest of the World)

• Darbepoietin biosimilars in less regulated markets

• Next generation biologic Erythropoiesis Stimulating Agents (ESA) in less regulated markets

 

 

 

2) G-CSF and GM-CSF

 

• 2012 Sales of Branded G-CSF Products in Regulated Markets

• 1st Generation Branded G-CSF Products in Regulated Markets

• Biosimilar 1st Generation G-CSF Products in Regulated Markets

• Next Generation Branded G-CSF Products in Regulated Markets

• Biosimilar Next Generation G-CSF Products in Regulated Markets

• 1st Generation G-CSF Products in Non-Regulated Markets: India

• 1st Generation G-CSF Products in Non-Regulated Markets: China & Taiwan

• 1st Generation G-CSF Products in Non-Regulated Markets – Korea

• 1st Generation G-CSF Products in Non-Regulated Markets – Latin America

• 1st Generation G-CSF Products in Non-Regulated Markets: Other Territories

• Next Generation G-CSF Products in Non-Regulated Markets

• 1st and Next Generation GM-CSF Products in Regulated Markets

• 1st and Next Generation GM-CSF Products in Non-Regulated Markets

 

3 ) Thrombopoiesis-Stimulating Agents (TPO; IL-11)

 

• Thrombopoietin receptor (TPO-R) activators

• Interleukin-11 (IL-11) receptor activators

• Small molecule TPO-R Agonists

• Corporate TPO/IL-11 Receptor Agonist Product Portfolios and R&D Pipelines

 

4 ) Interferon

a) INTERFERON alpha

 

• Interferon alpha sales 2012 of branded products in regulated markets

• 1st generation Interferon alpha-2a in regulated markets

• 1st generation Interferon alpha-2a in non-regulated markets

• Next generation Interferon alpha-2a in regulated markets

• Next generation Interferon alpha-2a in non-regulated markets and biosimilars

• 1st generation Interferon alpha-2b in regulated markets

• 1st generation Interferon alpha-2b in non-regulated markets and biosimilars

• Next generation Interferon alpha-2b in regulated markets

• Next generation Interferon alpha-2b in non-regulated markets and biosimilars

• Other Interferon alpha sub-types

• Interferon alpha with not specified sub-type – 1/2

• Purified natural human interferon alpha

 

b) Consensus INTERFERONs

c) INTERFERON beta

 

• Interferon beta sales 2012 of branded products in regulated markets

• 1st generation Interferon beta-1a in regulated markets

• 1st generation Interferon beta-1a in non-regulated markets and biosimilars

• 1st generation Interferon beta-1b in regulated markets

• 1st generation Interferon beta-1b in non-regulated markets and biosimilars

• 1st generation Interferon beta with not disclosed sub-type

• Next generation Interferon beta in regulated markets

• Purified natural human interferon beta

 

d) INTERFERON gamma

e) Other INTERFERONs

5 ) Insulin

 

• 2012 Sales of branded recombinant human insulins in regulated markets

• 2012 Sales of branded short-acting recombinant human insulin analogs in regulated markets

• 2012 Sales of branded long-acting recombinant human insulin analogs in regulated markets

• Rhu insulin (2nd generation) in regulated markets

• Biosimilar rhu insulin (2nd generation) in regulated markets

• Rhu insulin analogs (3rd generation) in regulated markets

• Biosimilar rhu insulin analogs (3rd generation) in regulated markets

• Ultra-long acting rhu insulin formulations and insulin analogs (4th generation)

• Ultra-fast acting rhu insulin formulations and insulin analogs (4th generation)

• Combinations of modern basal and prandial insulin & analogs (4th generation)

• Combinations of insulin & GLP-1 agonist (4th generation)

• Other combinations with insulin

• Oral and Transbuccal Insulins (5th generation)

• Inhaled and transdermal insulin

• Novel approaches for insulin therapy

 

Rhu insulin (2nd generation) in non-regulated markets: India

• Rhu insulin (2nd generation) in non-regulated markets: China

• Rhu insulin (2nd generation) in non-regulated markets: Other Territories

• Modern insulin analogs (3rd generation) in non-regulated markets

• Animal insulins (1st generation)

 

6 ) Coagulation Factors

 

• Sales of Recombinant Coagulation Factors for Hemophilia in 2012

• Human Plasma-Derived Coagulation Factor VIII Concentrates

• Recombinant Coagulation Factor VIII

• Human Plasma-Derived Coagulation Factor IX

• Recombinant Coagulation Factor IX

• Human Plasma-Derived Factor VII

• Recombinant Coagulation Factor VII

• Human Plasma-Derived Coagulation Factor Concentrates for Willebrand Disease

• Recombinant Human von Willebrand Factor (vWF)

• Human Plasma-Derived Fibrinogen

• Recombinant Human Fibrinogen

• Human Plasma-Derived Factor XI

• Human Plasma-Derived Factor X

• Recombinant Human Factor X

• Human Plasma-Derived Factor XIII

• Recombinant Human Factor XIII

• Alternative Procoagulants & Adjuncts

• Human Plasma-Derived Prothrombin Complex Concentrates

• Gene Therapy of Hemophilia

• Topical Human Plasma-Derived Fibrinogen and Thrombin Products

• Topical Plasma-Derived Thrombin Products

• Topical Recombinant Human Factor II (Prothrombin)

• Alternative Topical Hemostats

 

7 ) Human Growth Hormone (hGH)

 

• 2012 Sales of Branded Somatropin Products in Regulated Markets

• 2012 Sales of Selected Somatropin Products in Non-Regulated Markets

• 1st Generation: Somatropin in Regulated Markets

 

• 1st Generation: Biosimilar Somatropin in Regulated Markets

• 2nd Generation: Injectable Somatropin in Slow-release Formulation in Regulated Markets

• 2nd Generation: Injectable Long-acting Somatropin in Regulated Markets

• 2nd Generation: Injection-Free Somatropin in Regulated Markets

 

• 1st Generation: Somatropin Products in Non-Regulated Markets

• 2nd Generation: Injectable Long-Acting Somatropin Products in Non-Regulated Markets

• Non-Medical, Legal Uses of Somatropin

 

8 ) FSH, hCG and LH - Assisted Reproductive Technology (ART)

• Urinary FSH-Containing Products: Menotropins

• Recombinant Menotropins

• 1st Generation Purified Human Urinary FSH

• 2nd Generation Recombinant Human FSH

• Biosimilar Recombinant Human FSH

• 2nd Generation Rhu FSH in Non-Regulated Markets

• 3rd Generation Rhu FSH

• Purified Urinary Human Choriogonadotropin (hCG)

• Recombinant Human Choriogonadotropin (rhCG)

• Recombinant Human Luteinizing Hormone (rhLH)

• hCG Receptor Agonist

 

9 ) Thrombolytics & Fibrinolytics

 

• Non-fibrin selective (1st generation) Fibrinolytics

• Fibrin selective wild-type t-PA-based Fibrinolytics

• Fibrin selective engineered t-PA-based Fibrinolytics

• Non-t-PA-based Fibrinolytics

• Plasmin-based Fibrinolytics

• Adjunctive therapy to Fibrinolytics

• Biosimilar Thrombolytics and Fibrinolytics in Non-Regulated Markets

• Corporate Thrombolytic Product Portfolios and R&D Pipelines

 

10) Enzyme Replacement Therapies

 

• Gaucher Disease

• Fabry Disease

• Pompé Disease

• Hunter Disease (MPS II)

• Niemann Pick Diseases

• Mucopolysaccharidosis I (MPS I)

• San Filippo Syndrome (MPS IIIA)

• Morquio Syndrome (MPS IVA)

• Mucopolysaccharidosis VI (MPS VI)

• Tay-Sachs Disease

• Chronic Deficiency of Adenosine Deaminase

• Phenylketonuria / Hyperphenylalaninemia

• Other Enzyme Replacement Therapies

• Exocrine Pancreatic Insufficiency: Porcine-Derived ERT

• Exocrine Pancreatic Insufficiency: Recombinant ERT

• Others

 

 

 

To order this report:

Biopharmaceutical Industry: Competitor Analysis: Therapeutic Proteins – Biosimilars, Biobetters & Biosuperiors

 

Contact Clare: clare@reportlinker.com
US:(339) 368 6001
Intl:+1 339 368 6001

 


'/>"/>
SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Cell Therapeutics to Present at Upcoming Investor Conferences
2. Orexigen Therapeutics to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
3. ASGCT Annual Meeting to Highlight Latest Advances in Genetic and Cellular Therapeutics
4. Orexigen Therapeutics Reports Financial Results for the First Quarter Ended March 31, 2013
5. Emergent Technologies and Caisson Biotech Form Strategic Alliance with Local Health Care Providers to Improve Delivery and Performance of a Therapeutic Drug
6. Henri A. Termeer Joins Moderna Therapeutics Board Of Directors
7. Oxford BioTherapeutics and Boehringer Ingelheim Enter Collaboration to Discover Novel Antibody Targets in Cancer
8. Orexigen Therapeutics Commends the Campaign to End Obesitys Report on Long-term Returns of Obesity Prevention Policies
9. Cell Therapeutics to Report First Quarter Financial Results after Market on May 2, 2013
10. United Therapeutics Corporation To Announce First Quarter 2013 Financial Results Before Market Open On Thursday, April 25, 2013
11. Nanotherapeutics Awarded Defense Department Contract for Advanced Development and Manufacturing of Medical Countermeasures
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... SARASOTA, FL (PRWEB) , ... ... ... Inc. (RPS®) today announces publication of a United States multicenter, prospective clinical ... single use, disposable, point-of-care diagnostic test capable of identifying clinically significant acute ...
(Date:10/11/2017)... ... October 11, 2017 , ... At its ... announced Dr. Suneel I. Sheikh, the co-founder, CEO and chief research scientist of ... been selected for membership in ARCS Alumni Hall of Fame . ASTER ...
(Date:10/11/2017)... ... 11, 2017 , ... Proscia Inc ., a data ... titled, “Pathology is going digital. Is your lab ready?” with Dr. Nicolas Cacciabeve, ... and how Proscia improves lab economics and realizes an increase in diagnostic confidence.* ...
(Date:10/11/2017)... Austin, TX (PRWEB) , ... October 11, 2017 ... ... in August compared the implantation and pregnancy rates in frozen and fresh ... the contribution of progesterone and maternal age to IVF success. , After comparing ...
Breaking Biology Technology:
(Date:5/16/2017)... May 16, 2017   Bridge Patient Portal ... and MD EMR Systems , an electronic ... for GE, have established a partnership to build ... and the GE Centricity™ products, including Centricity Practice ... These new integrations will allow healthcare ...
(Date:4/19/2017)... The global military biometrics market ... by the presence of several large global players. The ... major players - 3M Cogent, NEC Corporation, M2SYS Technology, ... 61% of the global military biometric market in 2016. ... military biometrics market boast global presence, which has catapulted ...
(Date:4/13/2017)... SANTA MONICA, Calif. , April 13, 2017 /PRNewswire/ ... New York will feature emerging and ... Innovation Summits. Both Innovation Summits will run alongside the ... variety of speaker sessions, panels and demonstrations focused on ... east coast,s largest advanced design and manufacturing event will ...
Breaking Biology News(10 mins):